Combining Erlotinib Plus Bevacizumab and Gemcitabine Plus Capecitabine to Treat Advanced Pancreatic Cancer

NCT00260364 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

44

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: Gemcitabine 1000 mg/m2 iv days 1, 8, 15 of a 28 day cycle
DRUG: Capecitabine orally days 1 -21
DRUG: Erlotinib 100 mg orally days 1-28
DRUG: Bevacizumab 5 mg/kg intravenously every 2 weeks

Sponsor

Royal Marsden NHS Foundation Trust

Collaborators

[object Object]
[object Object]